Tag: Amyloid plaques

An estimated 7.2 million Americans age 65 and older are living with Alzheimer's in 2025 [1.7.2]. This staggering number fuels the urgent search for effective treatments, leading many to ask: What is the miracle drug for Alzheimer's?

The U.S. Food and Drug Administration (FDA) approved donanemab (brand name Kisunla) in July 2024 for treating early symptomatic Alzheimer's disease. This monoclonal antibody, developed by Eli Lilly, is specifically designed to target and help clear beta-amyloid plaques from the brain. Understanding the meaning of Donanemab involves grasping its innovative mechanism and potential to slow the disease's progression.